Source-grounded facts extracted from Neumora Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Neumora Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income $53.5 million.
“compared to $18.8 million for the same period in 2025. The decrease was primarily attributable to lower personnel-related costs. • Net Loss: The Company reported a net loss of $53.5 million for the first quarter of 2026, as compared to $68.0 million for the same period in 2025.”
Neumora Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.
“On March 30, 2026, Neumora Therapeutics, Inc. (“Neumora” or the “Company”) announced its financial results for the fourth quarter and full year ended December 31, 2025.”
Paul L. Berns was appointed as Chairman and Chief Executive Officer at Neumora Therapeutics, Inc..
“an Executive Employment Agreement, effective as of February 14, 2025, with Paul L. Berns, as the Company’s Chairman and Chief Executive Officer”
Henry Gosebruch departed as President and Chief Executive Officer at Neumora Therapeutics, Inc..
“the Company has entered into a Separation Agreement, dated February 14, 2025, with Henry Gosebruch, the Company’s former President and Chief Executive Officer”
Kaya Pai Panandiker departed as Chief Commercial Officer at Neumora Therapeutics, Inc..
“Kaya Pai Panandiker will depart the Company and no longer serve as Chief Commercial Officer.”
Carol Suh changed role as Chief Strategy Officer at Neumora Therapeutics, Inc..
“Carol Suh will transition from the role of Chief Operating Officer to Chief Strategy Officer”
Jason Duncan was appointed as Chief Legal and Administrative Officer at Neumora Therapeutics, Inc..
“Jason Duncan will serve as Chief Legal and Administrative Officer”
Michael Milligan was appointed as Chief Financial Officer at Neumora Therapeutics, Inc..
“Michael Milligan will serve as Chief Financial Officer in addition to his current role as principal accounting officer”
Bill Aurora changed role as Chief Operating and Development Officer at Neumora Therapeutics, Inc..
“Bill Aurora, Pharm.D. will transition from the role of Chief Strategy Officer to Chief Operating and Development Officer”
Joshua Pinto changed role as President at Neumora Therapeutics, Inc..
“Joshua Pinto, Ph.D. will transition from the role of Chief Financial Officer to President”
Henry Gosebruch departed as President, Chief Executive Officer at Neumora Therapeutics, Inc..
“Henry Gosebruch will depart the Company and no longer serve as President, Chief Executive Officer or a member of the Board.”
Paul L. Berns changed role as Chief Executive Officer and Chairman of the Board at Neumora Therapeutics, Inc..
“Paul L. Berns, the Company’s Co-Founder and Executive Chairman of its Board of Directors (the “Board”), will transition to the roles of Chief Executive Officer and Chairman of the Board”
Neumora Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: net income net loss of $53.7 million.
“announced its financial results for the first quarter ended March 31, 2024”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.